In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus

Kathleen E. Brummel-Ziedins PhD1 | Matthew Gissel MS1 | Jacqueline Neuhaus MS2 | Álvaro H. Borges MD, MSc, PhD3,4 | David R. Chadwick MRCP, PhD5 | Sean Emery PhD6,7 | James D. Neaton PhD2 | Russell P. Tracy PhD1,8 | Jason V. Baker MD, MS9,10 | for the INSIGHT SMART, ESPRIT Study Groups

1Department of Biochemistry, University of Vermont, Colchester, Vermont, USA
2Department of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA
3Centre of Excellence for Health, Immunity, and Infections (CHIP), Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
4Institute for Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
5James Cook University Hospital, Middlesbrough, UK
6Faculty of Medicine, University of Queensland, Brisbane, Australia
7The Kirby Institute, University of New South Wales, Sydney, Australia
8Department of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont, USA
9Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
10Department of Infectious Diseases, Hennepin County Medical Center, Minneapolis, Minnesota, USA

Abstract

Background: Effective HIV treatment with antiretroviral therapy has prolonged survival and shifted causes of death to non-AIDS illnesses such as cardiovascular disease. We have shown that inflammation and HIV viral load associate with pro- and anticoagulant factor imbalances resulting in increased thrombin generation when mathematically modeled. We explore the hypothesis that factor compositional imbalance, corresponding to increased in silico thrombin generation, predicts mortality among HIV+ persons.

Methods: In a nested case-control study of HIV+ individuals on continuous antiretroviral therapy in two large trials, we evaluated cases (any non-violent mortality, n = 114) and matched controls (n = 318). Thrombin generation in response to a tissue-factor initiator for each individual was calculated by a mathematical model incorporating levels of factors (F)II, V, VII, VIII, IX, X, antithrombin, tissue factor pathway inhibitor, and protein C (PC) measured at study entry to the trials. In silico thrombin generation metrics included clot time, maximum rate (MaxR), maximum level (MaxL), and area under the curve (AUC).
Aberrant coagulation is a well-described consequence of HIV infection. Deficiencies in key anticoagulants such as protein C (PC) and antithrombin (AT) have been detected in HIV-infected patients, and risk for thromboembolic disease may increase at lower CD4+ counts. With the development and use of effective antiretroviral therapy (ART), morbidity and mortality have been reduced among HIV+ patients. However, rates of non-AIDS defining conditions, such as cardiovascular disease, have been increasing. Increases in many chronic diseases would be expected with prolonged life expectancy, but a key factor contributing to excess rates of non-AIDS events among treated HIV+ patients includes persistent abnormalities in systemic inflammation and coagulation activity. Higher levels of biomarkers such as d-dimer and interleukin-6 (IL-6) among HIV+ patients have been shown to be positively associated with anemia, cancer, cardiovascular disease, type 2 diabetes, progression to AIDS, and composite non-AIDS related clinical events and all-cause mortality. However, a mechanistic basis for the connection between HIV-associated alterations in coagulation activity and risk for a broad spectrum of non-AIDS defining diseases has yet to be elucidated.

Qualitative or quantitative alterations in the proteins and cells responsible for maintaining the hemostatic balance can result in morbidity and mortality. At the center of many hemostatic processes that regulate bleeding and clotting is the generation of thrombin. Thrombin generation is the central event in hemostasis, whereby the suppression of thrombin production and/or function has been proven to be an effective anticoagulant therapy. Thrombin generation assays can be used to define an individual’s phenotype through the use of the phases of thrombin generation (initiation, propagation, termination) which are governed by the underlying kinetic reactions and can provide descriptors of the coagulation process (eg, rates, levels, and timing of thrombin formation and inhibition). Studies in the healthy population have shown that thrombin generation dynamics differ largely between individuals, but are relatively stable over time in a given individual, supporting the concept that they may have utility as a phenotypic marker. The mechanism-based bridge between thrombin generation assays and individualized risk prediction is plasma composition–based computational modeling. Recently, computational models that kinetically describe the tissue-factor initiated coagulation process (extrinsic pathway) have been utilized to define an individual’s thrombin phenotype based upon their individual plasma composition of pro- and anticoagulant factors.

The central idea with this approach is that in any individual, the balance of the procoagulant and anticoagulant factor levels together act to generate a unique coagulation or thrombin phenotype upon a tissue-factor stimulus. We believe that the sum of developmental, environmental, genetic, nutritional, and pharmacological influences are reflected in the protein levels at any given time that specifically alter the synthesis and/or presentation of the proteins and active enzymes. We have described changes in thrombin generation and related these changes to plasma coagulation factor composition in the following groups: genetic bleeding tendencies and clotting tendencies, women undergoing in vitro fertilization, chronic obstructive pulmonary disease, stroke, rheumatoid arthritis, and cardiovascular disease. In all cases, thrombin generation was more pronounced in individuals with procoagulant vs bleeding tendencies. Individuals with acute conditions appeared to have...
more pronounced thrombin generation than individuals with chronic conditions.\textsuperscript{38,40} Individuals with inflammatory diseases displayed a wide range of thrombin generation.\textsuperscript{37,39} We previously used this approach to study the consequences of HIV viral replication.\textsuperscript{41} We found short-term increases in factor (F) VIII and decreases in both AT and PC when HIV replication increased after stopping ART; reciprocal changes occurred after initiating ART. The protein concentrations for both groups (treated and untreated HIV infection) were within the normal ranges for healthy individuals, however, these differences resulted in significantly increased thrombin generation during untreated HIV infection, which was shown to be reversible with ART treatment. Whether this increased procoagulant potential translates into a higher risk of adverse clinical endpoints is unknown. In this nested case-control study, we report associations between mortality risk and computationally generated thrombin generation among HIV+ patients treated with ART.

2 | PATIENTS AND METHODS

2.1 | Study population

The study design was a nested case-control study, sampling patients from the control arms (continuous use of ART) of two large, international HIV clinical outcome trials, Strategies for Management of Antiretroviral Therapy (SMART)\textsuperscript{42,43} and Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT).\textsuperscript{44} In SMART, 5472 HIV-positive adults with CD4+ cell count >350 cells/mm\textsuperscript{3} in 33 countries were randomized to receive continuous ART with the goal of viral suppression (control group) or episodic ART guided by the CD4+ count. In ESPRIT, 4111 HIV-positive adults with CD4+ cell counts ≥300 cells/mm\textsuperscript{3} in 25 countries were randomized to receive continuous ART alone (control group) or continuous ART in combination with subcutaneous IL-2. Therefore, participants in the control arms of SMART and ESPRIT received continuous ART along with standard of care according to HIV treatment guidelines.

Cases were defined as death from any non-violent cause (n = 114) during follow-up (median 3 years), and were matched with controls based on age, enrollment date, study, and continent (three controls for every one case). Twenty-four controls were omitted due to an insufficient blood sample to measure factor levels; the remainder (n = 318) were included in our analyses. All participants provided written informed consent.

2.2 | Measurement of factor levels and other biomarkers

Blood was collected using EDTA (ethylenediaminetetraacetic acid) tubes and plasma was processed, frozen at −70°C, and stored at a central repository until analysis. Procoagulants FII, FV, FVII(a), FVIII, FIX, and FX were measured using an ELISA (Enzyme Research Laboratories, South Bend, IN); analytical inter-assay coefficients of variation (CV) range for these measures were 6.4%-11.1%, 9.6%-10.8%, 6.7%-12.2%, 3.8%-5.2%, 7.4%-7.8% and 5.8%-8.0%, respectively. AT was measured on a Stago STA-R analyzer (Stago Diagnostics, Parsippany, NJ); with a CV range of 2.6%-10.2%. PC and tissue factor pathway inhibitor (TFPI) were measured using ELISAs (Stago Diagnostics and R&D Systems, Minneapolis, MN, respectively). Corresponding CV ranges were 5.5%-6.2% and 8.8%-11.3%. The assays were standardized with EDTA plasma. All measurements used the sample collected at trial entry. Factors are expressed as percentages of the mean values in the healthy population.

IL-6 was measured by ELISA (R&D Systems). d-dimer was measured using the Liatest D-DI (Stago Diagnostics) for SMART or on a VIDAS instrument (BioMerieux Inc., Durham, NC) for ESPRIT. High-sensitivity C-reactive protein (hsCRP) was measured by ELISA (Siemens Diagnostics, Munich, Germany for SMART and R&D Systems for ESPRIT).

2.3 | Computational model of thrombin generation

Mathematical simulations of tissue factor-initiated thrombin generation were produced as previously described.\textsuperscript{45} For each individual, concentrations of procoagulants FII, FV, FVII(a), FVIII, FIX, and FX and anticoagulants TFPI, AT, and PC are electronically "exposed" to 5 pM tissue factor (TF) in the presence of 1 nmol/L thrombomodulin. Simulated reactions were solved for thrombin over a 1200 seconds time frame. Individual profiles can be summarized by parameters describing the initiation, propagation, and termination phases of in silico thrombin generation: maximum level of thrombin generation (MaxL), maximum rate of thrombin generated (MaxR), time to 10 nmol/L thrombin (clot time), and total thrombin generated (area under the curve [AUC]).\textsuperscript{46} Results for a particular group of individuals are graphically presented as a curve, which represents the mean thrombin concentration at each second of the reaction (± standard error of the mean). In silico thrombin generation from a hypothetical "control" is defined as all factors set at 100% of the mean physiologic concentration for each factor.

To determine which factor(s) were responsible for differences between cases and controls, we used a previously described procedure\textsuperscript{39,40} in which each of the individuals in the mortality group had one of the factor levels sequentially adjusted to the mean of the control group and the reaction rerun with a 5 pmol/L TF stimulus and in silico thrombin outputs recalculated. This process was repeated for each factor (and expanded to multiple factors simultaneously). The impact of a given factor was evaluated by quantifying the differences between various thrombin generation parameters pre- and post-adjustment.

2.4 | Statistical methods

We evaluated the effect of variables used to describe the initiation, propagation, and termination phases of thrombin generation, baseline characteristics, and initial protein concentrations on the risk of mortality with conditional logistic regression analyses for matched case-control studies. Odds ratios (OR) for mortality per 1 log\textsubscript{2} increase in factor levels and modeling parameters are cited. A 1 log\textsubscript{2}}
increase corresponds to a two times higher factor level or modeling parameter. To assess whether associations between maximum thrombin level and mortality varied by subgroups, an interaction term (product of log₂ level and subgroup indicator) was included in the logistic models. The effect of adjusting for individual factor levels on the maximum level OR for mortality was assessed.

3 | RESULTS

3.1 | Participant characteristics

Table 1 presents the participant demographic and clinical characteristics at trial entry. Distribution of underlying causes of death are included in Table 2, with the most frequent causes being non-AIDS defining cancer (n = 27; 23.7%), unknown (n = 16; 14.0%), cardiovascular disease (CVD) (n = 15; 13.2%), unwitnessed death (n = 12; 10.5%), liver disease (n = 10; 8.8%) and AIDS (n = 10; 8.8%). The median age was 46, and 81% were male. When compared to controls, cases had higher prevalence of viral hepatitis co-infection, prior CVD, smoking, and use of blood pressure-lowering therapy. Baseline use of non-nucleoside reverse transcriptase inhibitors (48.2%), protease inhibitors (44.7%), abacavir (24.8%), and tenofovir (10.2%) was similar between cases and controls. Cases were less likely to be virologically suppressed and had significantly higher levels of high-sensitivity C-reactive protein (hsCRP), IL-6, and D-dimer.

### TABLE 1 Participant demographic and clinical characteristics

|                          | Cases     | Controls  | P-valuea |
|--------------------------|-----------|-----------|----------|
| Number                   | 114       | 318       | N/A      |
| Age (median, IQR)        | 47 (40-54)| 46 (40-53)| N/A      |
| Female (%)               | 19.3      | 19.2      | 0.98     |
| Black race (%)           | 20.2      | 17.3      | 0.36     |
| White race (%)           | 73.7      | 72.3      |          |
| Other race (%)           | 6.1       | 10.4      |          |
| BMI (median, IQR)        | 23.4 (21.2-27.1) | 24.5 (22.6-26.9) | 0.18 |
| CD4+ (cells/mm³) (median, IQR) | 460 (371-630) | 499 (405-660) | 0.15 |
| Nadir CD4+ (cells/mm³) (median, IQR) | 194 (84-297) | 201 (98-320) | 0.16 |
| HIV RNA (% ≤500 copies/mL) | 66.7 | 76.1 | 0.036 |
| Hepatitis B or C co-infection (%) | 33.7 | 18.6 | 0.002 |
| BP-lowering treatment (%) | 23.7 | 15.4 | 0.025 |
| Lipid lowering treatment (%) | 19.3 | 15.7 | 0.40 |
| Diabetes (%)             | 8.8       | 7.2       | 0.65     |
| Prior CVD (%)            | 9.6       | 3.1       | 0.005    |
| Current smokerb (%)      | 59.3      | 37.9      | 0.009    |
| Total cholesterolb (mg/dL) (median, IQR) | 190 (165-238) | 202 (176-234) | 0.39 |
| HDL cholesterolb (mg/dL) (median, IQR) | 40 (31-53) | 41 (33-50) | 0.68 |
| LDL cholesterolb (mg/dL) (median, IQR) | 111 (84-134) | 111 (88-133) | 0.64 |
| Triglyceridesb (mg/dL) (median, IQR) | 168 (110-251) | 219 (149-324) | 0.32 |
| Total/HDL ratiob (median, IQR) | 4.5 (3.6-6.4) | 5.1 (3.8-6.5) | 0.62 |
| hsCRP (µg/mL) (median, IQR) | 3.10 (1.59-7.61) | 1.77 (0.79-3.84) | 0.005 |
| Interleukin-6 (pg/mL) (median, IQR) | 3.10 (2.10-4.48) | 1.90 (1.30-3.00) | <0.001 |
| D-dimer (µg/mL) (median, IQR) | 0.34 (0.23-0.54) | 0.26 (0.15-0.39) | 0.008 |

BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; HDL, high density lipoprotein; hsCRP: high-sensitivity C-reactive protein; IQR, interquartile range; LDL, low density lipoprotein.

aFrom univariate conditional logistic regression model.
bAvailable only for SMART participants (n = 54 cases and 153 controls).
3.2 | The pro- and anticoagulant balance in HIV mortality

Concentrations of plasma factors (expressed as a percentage of mean physiologic values in the healthy population) are shown in Table 3. In the unadjusted comparisons, the cases had higher procoagulants FVIII \((P = 0.003)\) and FV \((P = 0.018)\), but lower anticoagulants PC \((P = 0.002)\) and AT \((P = 0.034)\). After adjustment for age, sex, and race, FVIII \((OR 1.80; 95\% CI 1.16-2.80; P = 0.009)\), FV \((OR 1.73; 95\% CI 1.10-2.71; P = 0.017)\), and PC \((OR 0.45; 95\% CI 0.26-0.77; P = 0.003)\) remained significantly associated with mortality risk.

3.3 | Thrombin generation

The mean thrombin generation (±SEM) for cases and HIV+ controls are shown in Figure 1 along with a dashed line representing the 100% mean physiologic curve. Thrombin generation was increased, representing a more procoagulant potential, in both groups of HIV+ individuals (cases and controls) over a mean physiologic thrombin profile, with mortality cases having the higher thrombin generating procoagulant potential when compared to controls. From the individual profiles, parameters that objectively characterize the kinetic reaction of thrombin generation (MaxR, MaxL, AUC, and clot time) were extracted and are presented by group in Table 4. The OR for mortality risk per log \(^2\) higher level for each thrombin generation parameter is also presented in Table 3. Although clot time was similar between the two groups, the thrombin generation parameters of MaxR \((P = 0.020)\), MaxL \((P = 0.012)\), and AUC \((P = 0.006)\) were significantly associated with increased mortality risk.

The association of thrombin generation was further evaluated by subgroups defined by traditional risk factors, with data for mortality risk by maximum thrombin levels presented in Table 5. There was no evidence of a significant interaction of subgroup by higher maximum thrombin level for mortality risk.

### TABLE 2 Distribution of underlying cause of death by study

|Cause of death | ESPRIT, n (%) | SMART, n (%) | Total, n (%) |
|---------------|--------------|--------------|--------------|
|AIDS          | 7 (11.7)     | 3 (5.6)      | 10 (8.8)     |
|Non-AIDS cancer| 14 (23.3)    | 13 (24.1)    | 27 (23.7)    |
|CVD            | 8 (13.3)     | 7 (13)       | 15 (13.2)    |
|Unwitnessed death | 7 (11.7) | 5 (9.3) | 12 (10.5) |
|Hepatic       | 7 (11.7)     | 3 (5.6)      | 10 (8.8)     |
|Infection     | 3 (5)        | 4 (7.4)      | 7 (6.1)      |
|CNS disease   | 3 (5)        | 0 (0)        | 3 (2.6)      |
|Renal         | 0 (0)        | 2 (3.7)      | 2 (1.8)      |
|Digestive system disease | 1 (1.7) | 1 (1.9) | 2 (1.8) |
|Respiratory disease | 0 (0) | 1 (1.9) | 1 (0.9) |
|Renal         | 3 (5)        | 6 (11.1)     | 9 (7.9)      |
|Unknown       | 7 (11.7)     | 9 (16.7)     | 16 (14)      |
|Total         | 60 (100)     | 54 (100)     | 114 (100)    |

CNS, central nervous system; CVD, cardiovascular disease.

### TABLE 3 Factor levels and odds ratios for mortality. Median (IQR) factor levels for cases and controls and odds ratios for mortality associated with a doubling of the factor

| Factor     | Cases median (IQR) | Controls median (IQR) | OR (95% CI)\(^a\) | P-value | Adjust. OR (95% CI)\(^b\) | P-value |
|------------|--------------------|-----------------------|-------------------|---------|--------------------------|---------|
| II (%)     | 101 (84-117)       | 105 (91-121)          | 0.56 (0.32-1)     | 0.049   | 0.63 (0.35-1.13)         | 0.12    |
| V (%)      | 111 (87-135)       | 98 (85-120)           | 1.72 (1.1-2.69)   | 0.018   | 1.73 (1.1-2.71)          | 0.017   |
| VII (%)    | 94 (77-112)        | 103 (84-124)          | 0.65 (0.41-1.02)  | 0.062   | 0.67 (0.41-1.09)         | 0.10    |
| VIII (%)   | 147 (110-189)      | 130 (100-163)         | 1.91 (1.25-2.92)  | 0.003   | 1.80 (1.16-2.8)          | 0.009   |
| IX (%)     | 96 (82-113)        | 97 (86-113)           | 0.83 (0.56-1.23)  | 0.36    | 0.84 (0.56-1.26)         | 0.40    |
| X (%)      | 90 (78-105)        | 93 (81-108)           | 0.76 (0.42-1.39)  | 0.38    | 0.74 (0.4-1.38)          | 0.35    |
| PC (%)     | 109 (91-126)       | 117 (100-125)         | 0.44 (0.27-0.74)  | 0.002   | 0.45 (0.26-0.77)         | 0.003   |
| TFPI (ng/mL) | 27 (21-35)  | 27 (22-32)            | 1.39 (0.91-2.12)  | 0.13    | 1.40 (0.9-2.17)          | 0.14    |
| AT (%)     | 127 (110-140)      | 130 (114-143)         | 0.47 (0.23-0.95)  | 0.034   | 0.51 (0.25-1.05)         | 0.068   |

AT, antithrombin; IQR, interquartile range; PC, protein C; TFPI, tissue factor pathway inhibitor.

\(^a\)Odds ratio for mortality per 1 \(\log_2\) higher factor level from unadjusted conditional logistic regression model.

\(^b\)OR for mortality per 1 \(\log_2\) higher factor level, adjusted for age, sex, and race.
3.4 | Factor contribution to thrombin generation

In order to determine which factors were responsible for the altered thrombin generation between cases and controls, each of the cases had their thrombin generation curves re-simulated with each factor level set to the median value of the corresponding factor concentration observed in the HIV control cohort. The protein with the largest impact using this methodology was AT. Figure 2A shows the disappearance of differences in simulated thrombin generation between the groups when the cases had their AT set to the median value for controls of 130% (with all other factor levels for cases left unchanged). Figure 2B shows a similar diminishing of thrombin generation differences was seen when a combination of both FV and FVIII in cases were altered to the median values in the controls (111% and 147%, respectively).

This modeling approach was recapitulated with conditional logistic regression. The association between mortality and MaxL of thrombin generation was adjusted for each of the individual factors separately, and the OR for mortality associated with a doubling of MaxL was determined (Table 6). Individual adjustment for FV, FVIII, AT, or PC demonstrated the largest attenuation in the association between mortality and MaxL. In addition, adjustment of FV and FVIII together had the most substantial impact on attenuating the association with mortality.

4 | DISCUSSION

We present data demonstrating for the first time that risk for all-cause mortality among HIV+ patients receiving continuous ART is associated with a factor compositional imbalance that corresponds to an increase in simulated thrombin generation. Mortality was associated with increased inflammation, d-dimer, and an altered pro- and anticoagulant balance with higher levels of FV and FVIII and lower levels of PC and AT, yielding a higher procoagulant state among cases of non-violent mortality when compared with controls. These findings expand our understanding of HIV-associated abnormalities in coagulation biology and the consequences for mortality from a broad spectrum of disease, both CVD and non-CVD related.

We have shown in previous analyses of different pathologic states that normal range variation in coagulation factor composition can modulate the relative severity of the thrombin generation defect. The balance between these procoagulant and anticoagulant processes provides a defense against excessive fluid loss (hemorrhage) and against inappropriate vascular occlusion (thrombosis). Previous studies have shown that in HIV+ patients, there exists lower PC and protein S and elevated d-dimer and von Willebrand factor compared to HIV- controls. Higher fibrinogen has also been identified in HIV+ patients. We have also shown from the SMART study that increased HIV replication after stopping ART correlated with increased levels of FVIII and decreased levels of AT and PC, resulting in increased thrombin generation in this computational model. In this current study, both groups of ART-treated HIV+ patients had higher average AT than the mean physiologic population. This finding is in agreement with Hsue et al, who also found higher AT levels in HIV patients (both untreated and those receiving ART) compared to uninfected controls. That study found the higher AT levels contributing to a relatively decreased thrombotic state. In contrast, our HIV+ cohort had a significantly higher prothrombotic state.
potential than the hypothetical control with all factors at mean physiologic levels despite the increase in AT. This increased AT as-
sisted in mediating the combined effects of higher prothrombotic
factors and decreased TFPI, when compared to physiologic means,
which were found in both groups of this HIV+ population. As seen
in Figure 2B, an alteration of the concentrations of FV and FVIII in
the cases to the level seen in the controls diminished the observed
differences in thrombin generation between the two groups. This
particular combination is notable because they are the two proco-
factors of the coagulation system, converted by thrombin to the
active forms FVa and FVIIIa.51–53 These proteins are the respective
cofactors of the prothrombinase (FVa–FXa) and intrinsic tenase
(FVIIIa–FIXa) complex, with the intrinsic tenase being the principal
generator of FXa and subsequent thrombin generation.

Thrombin’s procoagulant activity is neutralized by the plasma
serine proteinase inhibitor AT and through the PC anticoagulant
pathway. The PC anticoagulant pathway plays a major role in the
balance of procoagulation and anticoagulation, by providing a dy-
namic inhibitory system to regulate thrombin production. Activated
protein C, produced by the thrombin–thrombomodulin complex,
inactivates the cofactors FVa and FVIIia,54 thereby downregulating
further generation of thrombin and stopping clot propagation. In this
study, it is the suppression of the anticoagulants PC and AT that al-

TABLE 5 Mortality risk by maximum thrombin level (MaxL) for key subgroups

| Case Variables | Cases | Controls | OR (95% CI) | P-valuea | P-valueb |
|---------------|-------|----------|-------------|-----------|-----------|
|               | Number | Med (IQR) | Number | Med (IQR) |            |            |
| Age           |        |          |          |            |           |           |
| ≤50 years     | 69     | 72 (49-98) | 217     | 53 (31-87) | 1.49 (1.14-1.96) | 0.004 | 0.15 |
| >50 years     | 45     | 67 (38-96) | 101     | 55 (36-87) | 1.08 (0.77-1.52) | 0.65 |       |
| Sex           |        |          |          |            |           |           |
| Male          | 92     | 62 (42-95) | 257     | 51 (33-81) | 1.32 (1.04-1.67) | 0.022 | 0.78 |
| Female        | 22     | 84 (74-108) | 61     | 77 (41-108) | 1.43 (0.85-2.4) | 0.18 |       |
| Race          |        |          |          |            |           |           |
| Black         | 23     | 72 (49-117) | 55     | 75 (54-113) | 1.04 (0.67-1.62) | 0.87 | 0.25 |
| Other         | 91     | 67 (42-93) | 263     | 50 (30-83) | 1.39 (1.1-1.76) | 0.006 |       |
| Hepatitis coinfection | | | | | | |
| Yes           | 36     | 80 (57-116) | 50     | 71 (57-97) | 1.46 (0.87-2.43) | 0.15 | 0.52 |
| No            | 78     | 65 (38-91) | 268     | 50 (31-82) | 1.21 (0.95-1.53) | 0.12 |       |
| HIV RNA       |        |          |          |            |           |           |
| ≤500 copies/mL| 76     | 67 (43-88) | 242     | 51 (31-81) | 1.34 (1.04-1.74) | 0.026 | 0.59 |
| >500 copies/mL| 38     | 84 (48-115) | 76     | 69 (44-100) | 1.18 (0.81-1.74) | 0.39 |       |
| IL-6          |        |          |          |            |           |           |
| <2.11 pg/mL   | 30     | 53 (42-76) | 185     | 52 (34-81) | 1.08 (0.74-1.59) | 0.69 | 0.33 |
| ≥2.11 pg/mL   | 80     | 74 (48-112) | 133    | 59 (33-89) | 1.36 (1.04-1.78) | 0.023 |       |

Cl, confidence interval; IQR, interquartile range; OR, odds ratio.
aConditional logistic regression OR for mortality per 1 log$_2$ higher level. 
bP-value for interaction.
events are a precious resource in this context, and we did not have any additional plasma available to perform in vitro thrombin generation assays. As computational modeling has made advancements into the area of predictive modeling of hemostatic status, ultimately having input concentrations of both antigen and functional activity would be optimal, and (iv) Any coagulation related genetic mutations having input concentrations of both antigen and functional activity would be suboptimal, and (v) Any coagulation related genetic mutations having input concentrations of both antigen and functional activity would be suboptimal, and (vi) Any coagulation related genetic mutations having input concentrations of both antigen and functional activity would be suboptimal, and (vii) Any coagulation related genetic mutations having input concentrations of both antigen and functional activity would be suboptimal.

Determining who is at risk for mortality from thrombotic disorders is difficult because the pathogenesis is complicated and multifactorial. Risk predictions for thrombotic-related outcomes are mostly based upon genetic factors (AT, PC, and protein S deficiencies; FV, FIX, FXI, and FXII mutations), increases in coagulation factors (notably FVIII, FIX, FXII, and environmental factors (obesity, oral contraceptive use, hormone replacement therapy, age, alcohol use, and potentially smoking). The heterologous presence of any of these circumstances in any individual may still be asymptomatic and does not ordinarily necessitate clinical intervention. In HIV+ patients, ART reduces but does not appear to fully normalize abnormalities in coagulation activation. In this study, all HIV+ patients were on ART therapy, and we show that that residual abnormalities in coagulation factor composition (FV, FVIII, PC, AT) in part, resulting from ongoing inflammation (eg, reflected in IL-6 levels), promote FXa activity which can become an important contributor to the excess thrombin generation observed among mortality cases. Having predictive models that evaluate each individual’s specific blood coagulation profile may better inform mortality risk, and help identify potential treatment interventions, among ART-treated HIV+ persons.

**ACKNOWLEDGMENTS**

We’d like to thank the participants and investigators for the SMART and ESPRIT trials (see [42] for the complete list of SMART investigators and [44] for the complete list of ESPRIT investigators). The SMART...
study was funded by NIH grants U01-AI068641, U01-AI046362, and U01-AI042170. The ESPRIT study was funded by NIH grants U01-AI068641 and U01-AI46957. The ARRA-2 grant was funded by NIH Grants 3U01-AI068641-0451 and 3U01-AI06841-0551. This project is also supported by NIH grant R01-HL126542, United States Navy contract W911QY-15-C-0027, and by the UVM Department of Biochemistry. AHB is supported by Lundbeckfonden (grant R219-2016-762). AHB’s institution is supported by a grant from the Danish National Research Foundation (grant number DNRF126). Portions of this research were presented at the 2016 American Society of Hematology Annual Meeting.

RELATIONSHIP DISCLOSURES

DC received grants and personal fees from Pfizer. RPT is one of the owners of Haematologic Technologies, Inc. All other authors claim no conflicts of interest.

AUTHOR CONTRIBUTIONS

KBZ designed and performed the research, analyzed data, and wrote the manuscript. MG performed the research, analyzed data, and wrote the manuscript. JDN, RPT, and JVB designed, analyzed data, and wrote the manuscript. JN analyzed data and wrote the manuscript. AHB, DC, and SE critically evaluated the manuscript and provided edits. JDN, RPT, and JVB designed, analyzed data, and wrote the manuscript.

REFERENCES

1. Saif MW, Greenberg B. HIV and thrombosis: a review. AIDS Patient Care STDS. 2001;15:15–24.
2. Feffer SE, Fox RL, Orsen MM, Harjai KJ, Glatt AE. Thrombotic tendencies and correlation with clinical status in patients infected with HIV. South Med J. 1995;88:1126–1130.
3. Erbe M, Rickerts V, Bauersachs RM, Lindhoff-Last E. Acquired protein C and protein S deficiency in HIV-infected patients. Clin Appl Thromb Hemost. 2003;9:325–331.
4. Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS. 2001;15:311–320.
5. Baker JV. Chronic HIV disease and activation of the coagulation system. Thromb Res. 2013;132:495–499.
6. Bibas M, Biava G, Antinori A. HIV infection as a permanent, acquired risk factor for VTE. Nat Rev Cardiol. 2014;11:321.
7. Grund B, Baker JV, Deeks SG, et al. Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy. PLoS One. 2016;11:e0155100.
8. Muller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
9. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788–1795.
10. Duprez DA, Neuhaus J, Muller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7:e44454.
11. Borges AH, Weitz JI, Collins G, et al. Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. AIDS. 2014;28:1791–1796.
12. Borges AH, Silverberg MJ, Wentworth D, et al. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS. 2013;27:1433–1441.
13. Betene ADC, De Wit S, Neuhaus J, et al. Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;67:538–546.
14. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011;203:1637–1646.
15. Borges AH, O’Connor JL, Phillips AN, et al. Interleukin 6 is a stronger predictor of clinical events than high-sensitivity C-reactive protein or D-dimer during HIV infection. J Infect Dis. 2016;214:408–416.
16. Hoyer LW, Hemophil A. N Engl J Med. 1994;330:38–47.
17. Reitsma PH. Protein C deficiency: from gene defects to disease. Thromb Haemost. 1997;78:344–350.
18. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol. 2003;23:17–25.
19. Mann KG. Thrombin formation. Chest. 2003;124:45–105.
20. Davies EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost. 2006;32(Suppl 1):3–15.
21. Brummel KE, Paradis SG, Branda RF, Mann KG. Oral anticoagulation thresholds. Circulation. 2001;104:2311–2317.
22. Hemker HC, Al Dieri R, De Smedt E, Beguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006;96:553–561.
23. Ekkelboom JW, Weitz J. Anticoagulation therapy. Dabigatran and risk of myocardial infarction. Nat Rev Cardiol. 2012;9:260–262.
24. Brummel-Ziedins K, Vossen CY, Rosendaal FR, Umezaki K, Mann KG. The plasma hemostatic proteome: thrombin generation in healthy individuals. J Thromb Haemost. 2005;3:1472–1481.
25. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:14–15.
26. Brummel-Ziedins KE, Poilout RL, Mann KG. Thrombin generation: phenotypic quantitation. J Thromb Haemost. 2004;2:281–288.
27. Dargaud Y, Francillon S, Negrier C. Intraindividual thrombin generation measurement variability in healthy adults over a one year period. Thromb Res. 2009;124:237–238.
28. Brummel-Ziedins KE, Wolberg AS. Global assays of hemostasis. Curr Opin Hematol. 2014;21:395–403.
29. Brummel-Ziedins KE. Developing individualized coagulation profiling of disease risk: thrombin generation dynamic models of the pro and anticoagulant balance. Thromb Res. 2014;133(Suppl 1):S9–S11.
30. Brummel-Ziedins KE, Orfeo T, Rosendaal FR, et al. Empirical and theoretical phenotypic discrimination. J Thromb Haemost. 2009;7(Suppl 1):181–186.
31. Brummel-Ziedins KE, Branda RF, Butenas S, Mann KG. Discordant fibrin formation in hemophilia. J Thromb Haemost. 2009;7:825–832.
32. Brummel-Ziedins K, Rivard GE, Poilout RL, et al. Factor Vila replacement therapy in factor VII deficiency. J Thromb Haemost. 2004;2:1735–1744.
33. Gissel M, Whelihan MF, Ferris LA, Mann KG, Rivard GE, Brummel-Ziedins KE. The influence of prophylactic factor VIII in severe haemophilia A. Haemophilia. 2012;18:193–199.
34. Brummel-Ziedins K, Callas PW, Orfeo T, et al. Evaluating thrombin generation in a family with protein C deficiency. J Thromb Haemost. 2009;7:162–163.
35. Foley JH, Ferris L, Brummel-Ziedins KE. Characteristics of fibrin formation and clot stability in individuals with congenital type llb protein C deficiency. Thromb Res. 2012;129:e142–e146.
36. Brummel-Ziedins KE, Gissel M, Francis C, Queenan J, Mann KG. The effect of high circulating estradiol levels on thrombin generation during in vitro fertilization. Thromb Res. 2009;124:505–507.
37. Undas A, Jankowski M, Kaczmarek P, Sladek K, Brummel-Ziedins KE. Thrombin generation in chronic obstructive pulmonary disease: dependence on plasma factor composition. Thromb Res. 2011;128:e24–e28.
38. Gissel M, Undas A, Slawik A, Mann KG, Brummel-Ziedins KE. Plasma factor and inhibitor composition contributes to thrombin generation dynamics in patients with acute or previous cerebrovascular events. Thromb Res. 2010;126:262–269.
39. Undas A, Gissel M, Kwasny-Krochin B, Glusko P, Mann KG, Brummel-Ziedins KE. Thrombin generation in rheumatoid arthritis: dependence on plasma factor composition. Thromb Haemost. 2010;104:224–230.
40. Brummel-Ziedins K, Undas A, Orfeo T, et al. Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. J Thromb Haemost. 2008;6:104–110.
41. Baker JV, Brummel-Ziedins K, Neuhaus J, et al. HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation. J Am Heart Assoc. 2013;2:e000264.
42. SMART Study Group, El-Sadr WM, Lundgren J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296.
43. SMART Study Group, Emery S, Neuhaus JA, et al. Major clinical outcomes in antiretroviral therapy (ART)-naïve patients and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197:1133–1144.
44. INSIGHT-ESPRIT Study Groups, SILCAAT Scientific Committee, Abrams D, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009;361:1548–1559.
45. Brummel-Ziedins KE, Orfeo T, Callas PW, Gissel M, Mann KG, Bovill EG. The prothrombotic phenotypes in familial protein C deficiency are differentiated by computational modeling of thrombin generation. PLoS One. 2012;7:e44378.
46. Brummel-Ziedins KE, Orfeo T, Gissel M, Mann KG, Rosendaal FR. Factor Xa generation by computational modeling: an additional discriminator to thrombin generation evaluation. PLoS One. 2012;7:e29178.
47. Brummel-Ziedins K. Models for thrombin generation and risk of disease. J Thromb Haemost. 2013;11(Suppl 1):212–223.
48. Jong E, Louw S, van Gorp EC, Meijers JC, ten Cate H, Jacobson BF. The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals. Thromb Haemost. 2010;104:1228–1234.
49. Madden E, Lee G, Kotler DP, et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS. 2008;22:707–715.
50. Hsue PY, Scherzer R, Grunfeld C, et al. HIV infection is associated with decreased thrombin generation. Clin Infect Dis. 2012;54:1196–1203.
51. Nesheim ME, Mann KG. Thrombin-catalyzed activation of single chain bovine factor V. J Biol Chem. 1979;254:1326–1334.
52. Fay PJ. Subunit structure of thrombin-activated human factor VIII. Biochim Biophys Acta. 1988;952:181–190.
53. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood. 2002;100:148–152.
54. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 1989;264:4743–4746.
55. Rana S, Yang L, Hassanian SM, Rezaie AR. Determinants of the specificity of protease-activated receptors 1 and 2 signaling by factor Xa and thrombin. J Cell Biochem. 2012;113:977–984.
56. Pryzdial EL, Sutherland MR, Ruf W. The procoagulant envelope virus surface: contribution to enhanced infection. Thromb Res. 2014;133(Suppl 1):S15–S17.
57. Rezaie AR. Protease-activated receptor signalling by coagulation proteases in endothelial cells. Thromb Haemost. 2014;112:876–882.
58. Ay C, Dunkler D, Pirk C, et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica. 2012;97:1158–1164.
59. Yamamoto M, Yoshinaga K, Matsuyama A, et al. Plasma D-dimer level as a mortality predictor in patients with advanced or recurrent colorectal cancer. Oncology. 2012;83:10–15.
60. Becattini C, Lignani G, Masotti L, Forte MB, Agnelli G. D-dimer for risk stratification in patients with acute pulmonary embolism. J Thromb Thrombolysis. 2012;33:48–57.
61. Wen D, Du X, Dong JZ, Zhou XL, Ma CS. Value of D-dimer and C reactive protein in predicting inhospital death in acute aortic dissection. Heart. 2013;99:1192–1197.
62. van Boven HH, Lane DA. Antithrombin and its inherited deficiency states. Semin Hematol. 1997;34:188–204.
63. Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombosis. Thromb Haemost. 2001;85:584–595.
64. Borgeil D, Gandrille S, Aiach M. Protein S deficiency. Thromb Haemost. 1997;78:351–356.
65. Folsom AR, Cushman M, Tsai MY, et al. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood. 2002;99:2720–2725.
66. Franco RF, Trip MD, ten Cate H, et al. The 20210 G→A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol. 1999;104:50–54.
67. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152–155.
68. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood. 2000;95:3678–3682.
69. Lavigne G, Mercer E, Quere I, Dauzat M, Gris JC. Thrombophilic families with inheritably associated high levels of coagulation factors VIII, IX and XI. J Thromb Haemost. 2003;1:2134–2139.
70. Lentz SR. Thrombosis in the setting of obesity or inflammatory bowel disease. Blood. 2016;128:2388–2394.
71. Rosing J, Tans G. Effects of oral contraceptives on hemostasis and thrombosis. Am J Obstet Gynecol. 1999;180:S375–S382.
72. Haapanen-Niemi N, Vuori I, Pasanen M. Public health burden of colorectal cancer. Oncology. 2012;83:10–15.
73. Catena C, Novello M, Dotto L, De Marchi S, Sechi LA. Serum lipoprotein(a) concentrations and alcohol consumption in hypertensive: possible relevance for cardiovascular damage. J Hypertens. 2003;21:281–288.
74. Thorneycroft IH, Goldzieher JW. Venous thromboembolism. A review. J Reprod Med. 2003;48:911–920.